HPV Versatile Position Versamune powered immunotherapies for oncology and infectious disease beyond HPV, highlighting clinical-stage progress and upcoming Phase 3 trials to engage potential licensing partners, contract manufacturers, and large pharma interested in T-cell engaging platforms.

Investment Readiness Capture investor interest by mapping the company’s current funding, recent $11M financing, and $73M total funding to potential strategic collaborations or co-development agreements with biotech funds and corporate venture arms seeking late-stage or near-term revenue opportunities.

Clinical Momentum Leverage milestones from Versamune HPV Phase 3 launch and Infectimune-based flu vaccine preclinical data to create sales narratives for CROs, clinical trial sites, and partnerships focused on immunotherapy delivery platforms and rapid enrollment strategies.

Small Team, Big Opportunity Target specialty contract manufacturers, regulatory affairs consultants, and biopharma service providers who can scale support for clinical programs and potential commercial preparation, given the lean 11- to 50-person organization and ongoing clinical trials.

Strategic Outreach Highlight participation in major conferences (H.C. Wainwright, AACR, IMMUNOLOGY2025) as touchpoints to initiate partner and collaboration conversations, offering sponsored panels, poster discussions, and sponsored data sharing to accelerate business development leads.